LLY Eli Lilly and Company

116.58
+0.35  (+0%)
Previous Close 116.23
Open 117.04
Price To Book 45.72
Market Cap 113179462591
Shares 970,830,868
Volume 2,611,127
Short Ratio 3.17
Av. Daily Volume 7,213,075

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data met primary endpoint - February 4, 2019. Data to be presented 2019.
Baricitinib
Atopic dermatitis
Phase 1/2 updated data noted ORR of 59% - October 6, 2018.
LOXO-292
RET-fusion non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other tumors
FDA approval (label expansion) announced June 5, 2018.
KEYTRUDA + chemo (KEYNOTE-021)
First-Line Nonsquamous Non-small cell lung cancer (NSCLC)
FDA approval announced September 27, 2018.
Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN
Migraine prevention
NDA filing announced November 14, 2018. Estimated PDUFA date November 13, 2019.
Lasmiditan - SPARTAN
Migraine
FDA label expansion announced January 31, 2019.
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 data released February 19, 2019. 10mg dose met primary endpoint. 5mg dose did not meet endpoint.
Tanezumab
Chronic low back pain
Phase 3 trial met primary endpoint - noted October 2, 2018.
Ultra rapid insulin
Diabetes
Phase 3 data from second trial released January 29, 2019 - co-primary endpoints met. Data from trial April 18, 2019 met 2/3 primary endpoints in 5mg arm but failed to meet endpoints in 2.5mg arm.
Tanezumab
Osteoarthritis
Phase 3 ongoing.
Tanezumab
Cancer pain
Phase 3 PFS data met primary endpoint but overall survival not improved. Will not seek regulatory approval.
Ramucirumab - RAINFALL
First-line gastric cancer
Phase 3 trial met primary endpoints - September 5, 2018.
Flortaucipir F 18 (Tau imaging agent)
Alzheimer's disease
Phase 3 data due 2019.
Empagliflozin
Heart failure with preserved ejection fraction (HFpEF)
Phase 3 data due 2019.
Empagliflozin
Heart failure with reduced ejection fraction (HFrEF)
Approval announced February 26, 2018.
Abemaciclib - MONARCH 3
HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)
Approved October 4, 2017.
Abemaciclib - MONARCH 1 and 2
Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and HR+, HER2- breast cancer
Phase 3 data released October 10, 2017 - primary endpoint not met.
Abemaciclib - JUNIPER
Thrid line KRAS mutation positive Non-small cell lung cancer (NSCLC)
Approval announced December 1, 2017.
Taltz
Psoriatic Arthritis
CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.
Baricitinib
Rheumatoid arthritis
FDA Approval announced November 26, 2018.
Larotrectinib (LOXO-101)
Solid tumors that harbor a TRK fusion.
Phase 3 trial met primary endpoint - noted June 25, 2018.
Empagliflozin
Type 1 Diabetes
Announced discontinuation of trial due to futility - June 12, 2018.
Lanabecestat (AZD3293) - AMARANTH
Early Alzheimer's disease
FDA approval announced May 13, 2019.
Ramucirumab REACH-2
Hepatocellular Carcinoma
Phase 3 PFS primary endpoint met - March 12, 2019.
Ramucirumab
Non-small cell lung cancer
Phase 3 trial met primary endpoint - noted June 28, 2018.
Ixekizumab
Axial Spondyloarthritis
Phase 3 trial met primary endpoint - July 19, 2018.
Tradjenta (linagliptin) - CARMELINA CV outcomes
Type 2 Diabetes
PDUFA date under priority review for sBLA announced March 5, 2019. No PDUFA date given - estimate July 2019.
Galcanezumab
Cluster headache
Phase 3 top-line data due 2021.
Mirikizumab (LY3074828)
Ulcerative Colitis
Phase 3 trial met composite endpoint - November 2018.
Trulicity REWIND CV outcomes
Type 2 diabetes
Phase 3 trial met primary endpoint of non-inferiority.
Tradjenta (linagliptin) - CAROLINA CV outcomes
Type 2 Diabetes
Phase 2 data due 2020.
N3pG Antipody
Alzheimer's disease
Phase 3 data due 2021.
Abemaciclib (Verzenio) - MonarchE
Breast cancer - adjuvant
Phase 3 data due 2020.
Mirikizumab
Psoriasis
Phase 3 data due 2020.
Baricitinib
Alopecia Areata
Phase 3 data due 2021.
Baricitinib
Systemic lupus erythematosus (SLE)
Phase 3 top-line data due 2020.
AM0010 (PEG-IL-10) - Sequoia
Pancreatic ductal adenocarcinoma (PDAC)
Phase 2 top-line data due late 2019.
AM0010 (PEG-IL-10) and Pembrolizumab - Cypress 1
Non-small cell lung cancer (NSCLC)
Phase 2 top-line data due 2H 2019.
AM0010 (pegilodecakin) and Nivolumab - Cypress 2
Non-small cell lung cancer (NSCLC)
Phase 1/2 initiation announced December 21, 2018.
LOXO-305
Refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin’s lymphomas (NHL)
Phase 3 data released January 18, 2018 did not meet primary endpoint. FDA had already awarded accelerated approval.
LARTRUVO (olaratumab)
Soft tissue sarcoma (STS)
Phase 3 data released April 22, 2019 met primary endpoint. Regulatory filing planned later in 2019.
Taltz (Ixekizumab)
Non-radiographic axial spondyloarthritis
Phase 3 data due 2019.
Taltz (Ixekizumab)
Psoriasis
Phase 3 trial to be initiated 2H 2019.
Tirzepatide
Type 2 Diabetes
Phase 3 trials to be initiated by YE 2019 with data due 2021.
Tirzepatide - Surpass
Type 2 Diabetes
Phase 3 trial to be initiated later in 2019.
Mirikizumab
Crohn's disease
Phase 3 data due 2019.
Dulaglutide
Type 2 diabetes

Latest News

  1. Why This Biotech Stock Succeeded In Colon Cancer As Others Struggled
  2. Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions
  3. Merck agrees $1bn deal to buy biopharmaceutical company Peloton
  4. Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock
  5. Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
  6. Better Buy: Eli Lilly vs. Pfizer
  7. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
  8. Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
  9. Lilly to Participate in UBS Global Healthcare Conference
  10. Pfizer's Eczema Candidate Meets All Goals in Phase III Study
  11. Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer
  12. 3 Stocks With Big News Coming at ASCO 2019
  13. The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, CVS, Marriott and TELUS
  14. 3 Top Diabetes Stocks to Watch in May
  15. Lilly to Participate in Bank of America Merrill Lynch Health Care Conference
  16. Top Research Reports for Alphabet, Eli Lilly & CVS Health
  17. Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
  18. Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma
  19. Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions
  20. Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues